Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

Immix Biopharma, Inc. (NASDAQ:IMMXGet Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 316,600 shares, an increase of 19.9% from the February 29th total of 264,100 shares. Based on an average daily trading volume, of 289,400 shares, the days-to-cover ratio is presently 1.1 days. Approximately 3.1% of the company’s shares are short sold.

Immix Biopharma Price Performance

IMMX stock opened at $3.07 on Friday. The business’s fifty day moving average is $3.29 and its 200-day moving average is $4.15. The company has a market cap of $61.00 million, a P/E ratio of -3.34 and a beta of 0.10. Immix Biopharma has a twelve month low of $1.40 and a twelve month high of $7.75.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IMMX. XTX Topco Ltd acquired a new position in shares of Immix Biopharma in the 1st quarter valued at $31,000. Renaissance Technologies LLC acquired a new position in shares of Immix Biopharma in the 1st quarter valued at $151,000. Virtu Financial LLC acquired a new position in shares of Immix Biopharma in the 1st quarter valued at $57,000. State Street Corp acquired a new position in shares of Immix Biopharma in the 2nd quarter valued at $100,000. Finally, Vanguard Group Inc. lifted its stake in shares of Immix Biopharma by 106.5% in the 3rd quarter. Vanguard Group Inc. now owns 105,125 shares of the company’s stock valued at $143,000 after purchasing an additional 54,220 shares during the period. Institutional investors and hedge funds own 11.26% of the company’s stock.

About Immix Biopharma

(Get Free Report)

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.

Further Reading

Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.